Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
Regeneron Pharmaceuticals Analyst Ratings
UnitedHealth Group Analyst Ratings
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,200
Intuitive Surgical Analyst Ratings
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,166
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,030, Maintains Buy Rating
Truist Financial Sticks to Its Buy Rating for Intuitive Surgical (ISRG)
Regeneron Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Barclays Adjusts Price Target on Intuitive Surgical to $510 From $490
Merck & Co. Poised for Growth: Strong Q2 Performance and Promising Pipeline Fuel Buy Rating
Buy Rating on UnitedHealth Group: Proactive Management and Strong Growth Outlook
Analysts' Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)
Outperform Rating Reaffirmed for Intuitive Surgical on Strong Q2 2024 Performance and Da Vinci 5 Launch Success
BMO Capital Adjusts Price Target on Merck to $150 From $148
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained
HSBC Raises Price Target on Eli Lilly to $1,100 From $880, Maintains Buy Rating
Deutsche Bank Raises Price Target on UnitedHealth Group to $632 From $562, Keeps Buy Rating